163 related articles for article (PubMed ID: 7240419)
1. Reversal of secondary hyperparathyroidism by cimetidine in chronically uremic dogs.
Jacob AI; Canterbury JM; Gavellas G; Lambert PW; Bourgoignie JJ
J Clin Invest; 1981 Jun; 67(6):1753-60. PubMed ID: 7240419
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Cimetidine treatment of azotemic secondary hyperparathyroidism.
Robinson MF; Johnson WJ; Heath H
J Clin Endocrinol Metab; 1982 Jun; 54(6):1206-9. PubMed ID: 6281294
[TBL] [Abstract][Full Text] [Related]
4. Phosphate homeostasis in cimetidine treated uremic dogs.
Jacob AI; Gavellas G; Canterbury JM; Lambert PW; Bourgoignie JJ
Adv Exp Med Biol; 1982; 151():167-76. PubMed ID: 7180647
[No Abstract] [Full Text] [Related]
5. Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (calcitriol) therapy.
Bellazzi R; Romanini D; Bacchella L; Nai M; Aprile C; Santagostino M; De Vincenzi A
Nephron; 1991; 57(3):273-82. PubMed ID: 2017266
[TBL] [Abstract][Full Text] [Related]
6. Failure of cimetidine to affect calcium homeostasis in familial primary hyperparathyroidism (multiple endocrine neoplasia, type 1).
Robinson MF; Hayles AB; Heath H
J Clin Endocrinol Metab; 1980 Oct; 51(4):912-4. PubMed ID: 6106649
[TBL] [Abstract][Full Text] [Related]
7. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.
Portale AA; Booth BE; Halloran BP; Morris RC
J Clin Invest; 1984 Jun; 73(6):1580-9. PubMed ID: 6547151
[TBL] [Abstract][Full Text] [Related]
8. Cimetidine and circulating calciotropic hormone levels in uremic patients: evidence for a suppressive effect on calcitonin secretion.
Sebert JL; Decourcelles PH; Morinière P; Calmette C; Gueris J; Makdassi R; Khassouf J; Andrejak M; Fournier A
Miner Electrolyte Metab; 1982 Dec; 8(6):293-9. PubMed ID: 7167135
[TBL] [Abstract][Full Text] [Related]
9. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.
Lopez-Hilker S; Galceran T; Chan YL; Rapp N; Martin KJ; Slatopolsky E
J Clin Invest; 1986 Oct; 78(4):1097-102. PubMed ID: 3760186
[TBL] [Abstract][Full Text] [Related]
10. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
[TBL] [Abstract][Full Text] [Related]
11. Blockers of beta and H2 receptors and secondary hyperparathyroidism in uraemia.
Makdassi R; Decourcelle PH; Moriniere P; Coevoet B; de Fremont JF; Kassouf J; Roussel A; Gheerbrand JD; Andrejak M; Fournier A
Proc Eur Dial Transplant Assoc; 1981; 18():642-7. PubMed ID: 7329992
[TBL] [Abstract][Full Text] [Related]
12. Reduction by cimetidine of serum parathyroid hormone levels in uremic patients.
Jacob AI; Lanier D; Canterbury J; Bourgoignie JJ
N Engl J Med; 1980 Mar; 302(12):671-4. PubMed ID: 7354765
[No Abstract] [Full Text] [Related]
13. Direct effect of the correction of acidosis on plasma parathyroid hormone concentrations, calcium and phosphate in hemodialysis patients: a prospective study.
Movilli E; Zani R; Carli O; Sangalli L; Pola A; Camerini C; Scolari F; Cancarini GC; Maiorca R
Nephron; 2001 Mar; 87(3):257-62. PubMed ID: 11287761
[TBL] [Abstract][Full Text] [Related]
14. Metabolic consequences of oral administration of 24,25-dihydroxycholecalciferol to uremic dogs.
Canterbury JM; Gavellas G; Bourgoignie JJ; Reiss E
J Clin Invest; 1980 Mar; 65(3):571-6. PubMed ID: 7354130
[TBL] [Abstract][Full Text] [Related]
15. The effects of intravenous and oral cimetidine in primary hyperparathyroidism.
Wiske PS; Epstein S; Norton JA; Bell NH; Johnston CC
Horm Metab Res; 1983 May; 15(5):245-8. PubMed ID: 6873872
[TBL] [Abstract][Full Text] [Related]
16. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
17. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol.
Lopez-Hilker S; Dusso AS; Rapp NS; Martin KJ; Slatopolsky E
Am J Physiol; 1990 Sep; 259(3 Pt 2):F432-7. PubMed ID: 2396669
[TBL] [Abstract][Full Text] [Related]
18. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
Slatopolsky E; Finch JL; Brown AJ; Ritter CS; Mizobuchi M; Plum LA; Clagett-Dame M; Sicinski RR; DeLuca HF
J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
[TBL] [Abstract][Full Text] [Related]
19. Dissociation between changes in immunoreactive parathormone and its biological indices induced by cimetidine in primary hyperparathyroidism.
van der Velden PC; Fischer HR; Hackeng WH; Schopman W; Koorevaar G; den Ottolander GJ; Silberbusch J
Acta Med Scand; 1981; 210(6):467-70. PubMed ID: 6277160
[TBL] [Abstract][Full Text] [Related]
20. Calcium and phosphorus metabolism in chronic uremia.
Fiaschi E; Mioni G; Maschio G; D'Angelo A; Ossi E
Nephron; 1975; 14(2):163-80. PubMed ID: 1093055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
